Current Consultations

Research Australia regularly contributes to the policy discussions on issues pertinent to Health and Medical Research. This can be through submissions or participating in consultations.

The following list is of consultations and invitations to make submissions which are relevant to health and medical research and/or health policy in Australia. Research Australia may not participate in every one however the list is updated regularly.

If you would like more information or you are aware of other consultations that should be included, please contact Greg Mullins, Head of Policy, Research Australia at greg.mullins@researchaustralia.org or on (03) 9662 9420.

Consultation Details
OPTIONS FOR THE FUTURE REGULATION OF ‘LOW RISK’ PRODUCTS

 

Due 12 May

In March 2015, the Expert Review of Medicines and Medical Devices Regulation (MMDR) made three recommendations to conduct further reviews of the regulation of ‘low risk’ products in Australia. This approach was supported by Government in its broader consideration of MMDR implementation.

The TGA is seeking submissions in response to a public consultation paper which contains a range of options for the future regulation of ‘low risk’ therapeutic goods (including maintenance of the status quo).

2030 STRATEGIC PLAN FOR INNOVATION, SCIENCE AND RESEARCH

 

Due 31May

 

The Australian Government has tasked Innovation and Science Australia with developing a Strategic Plan for the Australian innovation, science and research system out to 2030.

It will describe what Australia’s innovation system should look like in 2030 and will make recommendations as to how Australia can get there.

Innovation and Science Australia has released an Issues Paper which nominates six challenges central to shaping the strategy and is seeking feedback.

SOUTH AUSTRALIAN HEALTH and MEDICAL RESEARCH STRATEGY

 

Due 19 May

 

The South Australian government is consulting on is draft health and medical research strategy.

Questions include to what extent should SA health prioritise:

·       basic and biomedical research? (e.g. laboratory based research)

·       clinical research? (e.g. research into treatments or interventions)

·       population health research?  (e.g. population-based studies)

·       health systems and services research? (e.g. research into the effectiveness of health services)

 

EXTENDING CROWD SOURCED EQUITY FUNDING TO PRVATE COMPANIES

 

Due 6 June

Draft legislation has been released for public consultation to extend Crowd-sourced Equity Funding (CSEF) to proprietary companies.

CSEF allows a large number of individuals to make small financial investments in exchange for an equity stake in the company. The Government has already passed legislation that will establish a CSEF regime for public companies, commencing 29 September 2017.

The draft legislation will amend the Corporations Act 2001 to extend the CSEF regime to proprietary companies, improving access to finance for start ups and innovative small businesses. Investors will be protected by additional obligations that CSEF proprietary companies will be required to uphold, including: a minimum of two directors; financial reporting in accordance with accounting standards; audit requirements; restrictions on related party transactions; and minimum shareholder rights to participate in exit events.

Public Guidance on Employee Share Schemes

 

Due 7 June

The ATO is proposing to develop public guidance on Employees Share Schemes, consolidating previous guidance and rulings.

A consultation paper has been issued and lists some of the parameters for the proposed public guidance and seeks input on a range of key questions.  This initiative from the ATO builds on and consolidates a range of reforms to employee share schemes in recent years. Employee share schemes are of particular importance to cash limited start up companies, including in biotechnology, pharmaceuticals and medical technologies.